Acid sphingomyelinase regulates T_H2 cytokine release and bronchial asthma

Abstract

Abstract Background Allergic diseases and especially allergic asthma are widespread diseases with high prevalence in childhood, but also in adults. Acid sphingomyelinase (ASM) is a key regulator of the sphingolipid pathway. Previous studies defined the association of ASM with the pathogenesis of T H 1‐directed lung diseases like cystic fibrosis and acute lung injury. Here, we define the role of ASM in T H 2‐regulated allergic bronchial asthma. Methods To determine the role of Asm under baseline conditions, wild‐type (WT) and Asm −/− mice were ventilated with a flexiVent setup and bronchial hyperresponsiveness was determined using acetylcholine. Flow cytometry and cytokine measurements in bronchoalveolar lavage fluid and lung tissue were followed by in vitro T H 2 differentiations with cells from WT and Asm −/− mice and blockade of Asm with amitriptyline. As proof of principle, we conducted an ovalbumin‐induced model of asthma in WT‐ and Asm −/− mice. Results At baseline, Asm −/− mice showed better lung mechanics, but unaltered bronchial hyperresponsiveness. Higher numbers of Asm −/− T cells in bronchoalveolar lavage fluid released lower levels of IL‐4 and IL‐5, and these results were paralleled by decreased production of typical T H 2 cytokines in Asm −/− T lymphocytes in vitro. This phenotype could be imitated by incubation of T cells with amitriptyline. In the ovalbumin asthma model, Asm −/− animals were protected from high disease activity and showed better lung functions and lower levels of eosinophils and T H 2 cytokines. Conclusion Asm deficiency could induce higher numbers of T H 2 cells in the lung, but those cells release decreased T H 2 cytokine levels. Hereby, Asm −/− animals are protected from bronchial asthma, which possibly offers novel therapeutic strategies, for example, with ASM blockade.